171 related articles for article (PubMed ID: 32686733)
1. Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System.
Jiao XF; Li HL; Jiao XY; Guo YC; Zhang C; Yang CS; Zeng LN; Bo ZY; Chen Z; Song HB; Zhang LL
Sci Rep; 2020 Jul; 10(1):11955. PubMed ID: 32686733
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS).
Wu T; Shi Y; Zhu B; Li D; Li Z; Zhao Z; Zhang Y
Expert Opin Drug Saf; 2024 Mar; 23(3):313-321. PubMed ID: 37612600
[TBL] [Abstract][Full Text] [Related]
3. Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems.
Raschi E; Girardi A; Poluzzi E; Forcesi E; Menniti-Ippolito F; Mazzanti G; De Ponti F
Drug Saf; 2018 Aug; 41(8):745-752. PubMed ID: 29582393
[TBL] [Abstract][Full Text] [Related]
4. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS.
Fujimoto M; Hosomi K; Takada M
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):259-66. PubMed ID: 24472404
[TBL] [Abstract][Full Text] [Related]
5. Examining the Nocebo Effect of Statins Through Statin Adverse Events Reported in the Food and Drug Administration Adverse Event Reporting System.
Moon J; Cohen Sedgh R; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2021 Jan; 14(1):e007480. PubMed ID: 33161769
[TBL] [Abstract][Full Text] [Related]
6. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
[TBL] [Abstract][Full Text] [Related]
7. Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System.
Golomb BA; Verden A; Messner AK; Koslik HJ; Hoffman KB
Drug Saf; 2018 Apr; 41(4):403-413. PubMed ID: 29427042
[TBL] [Abstract][Full Text] [Related]
8. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
[TBL] [Abstract][Full Text] [Related]
9. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
McAdams M; Staffa J; Dal Pan G
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
[TBL] [Abstract][Full Text] [Related]
10. Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system.
Antonazzo IC; Poluzzi E; Forcesi E; Salvo F; Pariente A; Marchesini G; De Ponti F; Raschi E
Acta Diabetol; 2020 Jan; 57(1):71-80. PubMed ID: 31203438
[TBL] [Abstract][Full Text] [Related]
11. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
12. Eye disorders associated with newer antiepileptic drugs: A real-world disproportionality analysis of FDA adverse event reporting system.
Hu W; Chen L; Li H; Liu J
Seizure; 2022 Mar; 96():66-73. PubMed ID: 35124339
[TBL] [Abstract][Full Text] [Related]
13. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system.
Huang J; Jia Y; Sun S; Meng L
BMC Pharmacol Toxicol; 2020 Sep; 21(1):68. PubMed ID: 32938499
[TBL] [Abstract][Full Text] [Related]
14. Statin-associated ocular disorders: the FDA and ADRAC data.
Mizranita V; Pratisto EH
Int J Clin Pharm; 2015 Oct; 37(5):844-50. PubMed ID: 25939673
[TBL] [Abstract][Full Text] [Related]
15. Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews.
Han N; Oh JM; Kim IW
Sci Rep; 2020 Feb; 10(1):3116. PubMed ID: 32080337
[TBL] [Abstract][Full Text] [Related]
16. Effect of statins on blood pressure: Analysis on adverse events released by FDA.
You T; Liu XG; Hou XD; Wang XK; Xie HH; Ding F; Yi K; Zhang P; Xie XD
Clin Exp Hypertens; 2017; 39(4):325-329. PubMed ID: 28513233
[TBL] [Abstract][Full Text] [Related]
17. Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database.
Takada M; Fujimoto M; Yamazaki K; Takamoto M; Hosomi K
Drug Saf; 2014 Jun; 37(6):421-31. PubMed ID: 24743876
[TBL] [Abstract][Full Text] [Related]
18. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Chang JT; Staffa JA; Parks M; Green L
Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
[TBL] [Abstract][Full Text] [Related]
19. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS.
Ji HH; Tang XW; Dong Z; Song L; Jia YT
Clin Drug Investig; 2019 Mar; 39(3):319-330. PubMed ID: 30674039
[TBL] [Abstract][Full Text] [Related]
20. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports.
Fernández AB; Karas RH; Alsheikh-Ali AA; Thompson PD
Chest; 2008 Oct; 134(4):824-830. PubMed ID: 18689579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
